The pharmaceutical sector continued to rise sharply, with Sinotheopea, Shuangcheng Pharmaceutical, and Changjiang Health rising to the limit

News on December 7, the pharmaceutical sector continued to rise, setting off a wave of ups and downs, in vitro testing, CRO and other subdivisions have strengthened
.
From the perspective of individual stocks, Sinotherapeutical, Shuangcheng Pharmaceutical, Changjiang Health, etc.
, and many pharmaceutical stocks including Common Pharmaceutical, Guangshengtang and so on have followed suit
.
As of 10:14, Sinotherapeutics rose as much as 20%, with a quotation of 13.
86 yuan, a turnover of 53.
73 million, and a turnover rate of 9.
48%.

According to the data, Sinotherapeutics is an enterprise driven by R&D innovation, mainly engaged in the research and development, production and sales of generic drugs and CRO services
.
On the news, on December 5, 2022, researchers from the University of Cambridge in the United Kingdom published a research paper
titled "FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2" in the journal Nature.
The study mentions that ursodeoxycholic acid (UDCA), a drug for treating liver disease, can shut down ACE2 receptors, closing the door
for the virus to enter cells.
Sinotherapeutics disclosed in the investor relations activity record released on November 30 that the company's ursodeoxycholic acid capsule products will be commercially available
in the near future.
It is reported that its ursodeoxycholic acid capsule product was approved
on July 29 this year.
The company believes that products such as ursodeoxycholic acid capsules are expected to bring a good contribution
.
As of 10:14, Shuangcheng Pharmaceutical rose to the limit, with a quotation of 8.
75 yuan, a turnover of 311 million, and a turnover rate of 8.
99%.

The main business of Shuangcheng Pharmaceutical is the research and development, production and sales
of chemically synthesized peptide drugs.
The analysis believes that the reasons for the stock rise include medicine + generic drugs + hepatitis + assisted reproduction
.
Among them, in terms of generic drugs, the company has a relatively advanced
layout in the field of peptide generic drug preparations.
During the 2017 reporting period, the Company underwent a Pre-Approval Inspection (PAI)
for the registration of generic drugs (ANDA) by the US FDA.
The main products are Kitai (brand name) thymus fasine for injection, bivalirudin for injection, L-carnitine for injection, clindamycin hydrochloride for injection, famotidine for injection, somatostatin for injection, Chuanxiongzine phosphate for injection; In terms of hepatitis, the new indications of thymus method for injection of the company's peptide products include chronic hepatitis B; In addition, the company's product triptorelin acetate injection has obtained the registration approval of the State Food and Drug Administration, and triptorelin acetate injection is suitable for pituitary lowering adjustment required for infertility treatment (such as in vitro fertilization (IVF), gamete intratubal transfer (GIFT) and follicle maturation without adjuvant treatment.

As of 10:14, Changjiang Health also walked out of the price limit market, with a quotation of 5.
76 yuan, a turnover of 388 million, and a turnover rate of 5.
66%.

It is worth mentioning that the stock has risen 11 times
in the past year.
The company is engaged in the research and development, production and sales of pharmaceutical products, its main products include lyophilized powder needles, powder injections, escalator guides, hollow guides, solid guides, accessories and automotive profiles, guide rail blanks, channel steel
.
On the news, Changjiang Health announced on December 4 that its wholly-owned subsidiary Changjiang Pharmaceutical Investment intends to acquire 58% of the equity
of Suzhou Jianghe Pharmaceutical Co.
, Ltd.
held by Zhangjiagang Free Trade Zone Runzhigang International Trade Co.
, Ltd.
with its own funds of 39.
44 million yuan.
At present, Jianghe Pharmaceutical is conducting independent research and development of CH2101, which is in the clinical phase 1 stage and is progressing smoothly
.
CH2101 has obtained some research data, and it needs to be completed clinical research and approved by the national drug review department before it can be marketed, and the clinical progress, research results and review and approval results are uncertain
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.